<DOC>
	<DOCNO>NCT01005628</DOCNO>
	<brief_summary>After KFDA ( Korea Food Drug Administration ) approval new drug , annual report drug 's safety efficacy data must report Health Authority 6 year . In Observational study , investigate basic demographic , medical history , concomitant drug use , well dose information multiple myeloma patient use bortezomib ( Velcade ) .</brief_summary>
	<brief_title>Bortezomib ( Velcade ) - Regulatory Post Marketing Surveillance ( PMS )</brief_title>
	<detailed_description>After KFDA approval new drug , annual report drug 's safety efficacy data must report Health Authority 6 year . In Observational study , investigate basic demographic , medical history , concomitant drug use , well dose information multiple myeloma patient use bortezomib ( Velcade ) . We collect response rate accord EMBT ( European Group Blood Marrow Transplant ; non-profit organization base Netherlands promote transplantation haemopoietic stem cell donor source donor type relate basic clinical research , education , standardization , quality control , accreditation transplant procedure ) IMWG ( International Myeloma Working Group ) criteria adverse event assess efficacy safety . Observational Study - No investigational drug administer</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Patients newly prescribe bortezomib injection treatment multiple myeloma Patients hypersensitive bortezomib component bortezomib history hypersensitivity Patients severe hepatic impairment Pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Bortezomib postmarketing surveillance</keyword>
	<keyword>Korea bortezomib PMS</keyword>
</DOC>